Strong six-month sales help Boehringer build on stellar 2017

1 August 2018

Family-owned German drugmaker Boehringer Ingelheim has issued a statement related to its financial performance in first-half 2018, indicating the firm achieved “modest growth,” with net revenues of 8.6 billion euros ($10 billion).

Highlighting significant investments, particularly in the German and French markets, the firm claims that of some 80 development projects, 65% have “the potential for a therapeutic breakthrough or to be the first active ingredient in a new class.”

While the firm grew in all of its businesses, growth was down from last year, partly due to increased generic competition in the Japanese cardiovascular market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK